Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 10
2019 20
2020 36
2021 47
2022 42
2023 39
2024 20

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Results by year

Filters applied: . Clear all
Page 1
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, Letai A. DiNardo CD, et al. Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25. Blood. 2019. PMID: 30361262 Free PMC article.
B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML cells and treatment resistance. We report safety and efficacy of venetoclax with decitabine or azacitidine from a large, multicenter, phase 1b dose-escalation and expansion study. ...The media …
B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML cells and treatment resistance. We report safety and efficacy of …
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.
Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, Furudate K, Daver NG, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Tang G, Ravandi F, Kantarjian HM, DiNardo CD, Konopleva MY. Kim K, et al. Cancer. 2021 Oct 15;127(20):3772-3781. doi: 10.1002/cncr.33689. Epub 2021 Jul 13. Cancer. 2021. PMID: 34255353 Free PMC article.
The authors investigated the outcomes of patients with TP53(mut) AML who were treated with a 10-day decitabine and venetoclax (DEC10-VEN) (ClinicalTrials.gov identifier NCT03404193). METHODS: Patients with newly diagnosed AML received decitabine 20 mg/m(2) fo …
The authors investigated the outcomes of patients with TP53(mut) AML who were treated with a 10-day decitabine and venetoclax …
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. DiNardo CD, et al. Lancet Haematol. 2020 Oct;7(10):e724-e736. doi: 10.1016/S2352-3026(20)30210-6. Epub 2020 Sep 5. Lancet Haematol. 2020. PMID: 32896301 Free PMC article. Clinical Trial.
We hypothesised that venetoclax with 10-day decitabine could have improved activity in patients with newly diagnosed AML and those with relapsed or refractory AML, particularly in high-risk subgroups. ...Patients with favourable-risk cytogenetics (eg, t[15;17] or co …
We hypothesised that venetoclax with 10-day decitabine could have improved activity in patients with newly diagnosed AML and t …
Venetoclax with decitabine or azacitidine in the first-line treatment of acute myeloid leukemia.
Bouligny IM, Murray G, Doyel M, Patel T, Boron J, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Wages NA, Grant S, Maher KR. Bouligny IM, et al. EJHaem. 2023 Feb 24;4(2):381-392. doi: 10.1002/jha2.663. eCollection 2023 May. EJHaem. 2023. PMID: 37206255 Free PMC article.
Even less is known about the impact of the hypomethylating agent backbone. In this study, we demonstrate that decitabine-venetoclax is associated with a significantly higher rate of grade three or higher thrombocytopenia, but lower rates of lymphocytopenia compared …
Even less is known about the impact of the hypomethylating agent backbone. In this study, we demonstrate that decitabine-venetocla …
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.
Pollyea DA, Pratz K, Letai A, Jonas BA, Wei AH, Pullarkat V, Konopleva M, Thirman MJ, Arellano M, Becker PS, Chyla B, Hong WJ, Jiang Q, Potluri J, DiNardo CD. Pollyea DA, et al. Am J Hematol. 2021 Feb 1;96(2):208-217. doi: 10.1002/ajh.26039. Epub 2020 Nov 10. Am J Hematol. 2021. PMID: 33119898 Free article. Clinical Trial.
This analysis represents the longest-term follow-up for patients with acute myeloid leukemia (AML) treated with 400 mg of venetoclax plus azacitidine or decitabine. Adults with newly diagnosed AML ineligible for intensive chemotherapy were enrolled in an open-label, …
This analysis represents the longest-term follow-up for patients with acute myeloid leukemia (AML) treated with 400 mg of venetoclax …
A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML.
Levitz D, Saunthararajah Y, Fedorov K, Shapiro LC, Mantzaris I, Shastri A, Kornblum N, Sica RA, Shah N, Konopleva M, Gritsman K, Braunschweig I, Cooper DL, Pradhan K, Verma A, Feldman EJ, Goldfinger M. Levitz D, et al. Clin Cancer Res. 2023 Aug 1;29(15):2774-2780. doi: 10.1158/1078-0432.CCR-23-0842. Clin Cancer Res. 2023. PMID: 37341641
PURPOSE: Venetoclax (VEN) added to the hypomethylating agents (HMA) decitabine or azacitidine is the new standard of care for elderly patients with acute myeloid leukemia (AML) and is being evaluated in myelodysplastic syndrome (MDS). Current dosing of HMA/VEN relie …
PURPOSE: Venetoclax (VEN) added to the hypomethylating agents (HMA) decitabine or azacitidine is the new standard of care for …
Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia.
Bouligny IM, Murray G, Ho T, Doyel M, Patel T, Boron J, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Wages NA, Grant S, Maher KR. Bouligny IM, et al. Res Sq [Preprint]. 2023 Jun 12:rs.3.rs-3015916. doi: 10.21203/rs.3.rs-3015916/v1. Res Sq. 2023. PMID: 37398154 Free PMC article. Updated. Preprint. No abstract available.
Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Wei Y, Xiong X, Li X, Lu W, He X, Jin X, Sun R, Lyu H, Yuan T, Sun T, Zhao M. Wei Y, et al. Cancer Sci. 2021 Sep;112(9):3636-3644. doi: 10.1111/cas.15048. Epub 2021 Jul 21. Cancer Sci. 2021. PMID: 34185931 Free PMC article.
Novel therapy to prevent relapse is urgently needed. Both the BCL-2 inhibitor venetoclax (VEN) and the hypomethylating agent decitabine (DEC) possess significant antitumor activity effects against AML/MDS. ...We therefore conducted a prospective study (ChiCTR1900025 …
Novel therapy to prevent relapse is urgently needed. Both the BCL-2 inhibitor venetoclax (VEN) and the hypomethylating agent decit …
Venetoclax resistance: mechanistic insights and future strategies.
Ong F, Kim K, Konopleva MY. Ong F, et al. Cancer Drug Resist. 2022 May 6;5(2):380-400. doi: 10.20517/cdr.2021.125. eCollection 2022. Cancer Drug Resist. 2022. PMID: 35800373 Free PMC article. Review.
In this review, we will provide a comprehensive summary of the known mechanisms of resistance to Venetoclax and discuss Venetoclax-based combination therapies. Key contributing factors to Venetoclax resistance include dependencies on alternative anti-apoptoti …
In this review, we will provide a comprehensive summary of the known mechanisms of resistance to Venetoclax and discuss Venetoclax …
190 results